AbbVie (NYSE:ABBV) Issues Q3 2025 Earnings Guidance

Key Points

• AbbVie has updated its Q3 2025 earnings guidance, projecting EPS between 1.740 and 1.780, significantly lower than the consensus estimate of 3.260.
• The company announced a quarterly dividend of $1.64, which will be paid on November 14th, resulting in an annualized yield of 2.8%.
• Analysts have shown increased confidence in AbbVie, with multiple upgrades, including Berenberg Bank raising their price target to $270.00.

AbbVie (NYSE:ABBV - Get Free Report) updated its third quarter 2025 earnings guidance on Friday. The company provided EPS guidance of 1.740-1.780 for the period, compared to the consensus EPS estimate of 3.260. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.380-10.580 EPS.

AbbVie Trading Down 1.1%

Shares of ABBV traded down $2.50 during trading hours on Friday, reaching $234.07. The stock had a trading volume of 6,539,471 shares, compared to its average volume of 6,498,375. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81. The firm has a 50-day moving average of $209.90 and a 200 day moving average of $195.87. The company has a market cap of $413.49 billion, a P/E ratio of 111.46, a P/E/G ratio of 1.43 and a beta of 0.51.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing the consensus estimate of $3.24 by ($0.27). The business had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.65 earnings per share. On average, sell-side analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, October 15th. AbbVie's payout ratio is presently 312.38%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ABBV shares. Berenberg Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating and raised their price objective for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. UBS Group set a $251.00 price target on shares of AbbVie in a research note on Friday. Wells Fargo & Company lifted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Daiwa America upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 7th. Finally, Guggenheim lifted their price target on shares of AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $228.22.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This trade represents a 19.29% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rakuten Securities Inc. grew its holdings in AbbVie by 26.5% in the second quarter. Rakuten Securities Inc. now owns 368 shares of the company's stock valued at $68,000 after purchasing an additional 77 shares during the last quarter. Binnacle Investments Inc lifted its position in AbbVie by 33.2% during the second quarter. Binnacle Investments Inc now owns 493 shares of the company's stock worth $92,000 after buying an additional 123 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of AbbVie in the 2nd quarter worth about $277,000. Redwood Financial Network Corp raised its holdings in shares of AbbVie by 10.8% during the 2nd quarter. Redwood Financial Network Corp now owns 1,649 shares of the company's stock valued at $306,000 after buying an additional 161 shares during the period. Finally, WFA of San Diego LLC acquired a new stake in AbbVie during the 2nd quarter valued at approximately $333,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.